Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-PCNSL: Pirtobrutinib, Sintilimab, Rituximab, and Methotrexate in Treatment-Naive PCNSL
NCT07350850Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirtobrutinib and sintilimab in primary central nervous system lymphoma (PCNSL) (2 cohorts), sponsored by Tongji Hospital. Primary endpoint: Complete Response Rate at 18 weeks. Started Dec 2025; status: recruiting.
02
Drugs
pirtobrutinibsintilimab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07350850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350850.